MaryjoJLechowiczMD

Hematology • Atlanta, GA

Hematologic Oncology

Professor, Hematology and Medical Oncology, Emory University School of Medicine

Join to view full profile

Dr. Lechowicz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lechowicz's full profile

Already have an account?

Office
1365 Clifton Rd NE
Atlanta, GA 30322
Phone+1 404-778-1900

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2000 - 2003
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1996 - 2000
SUNY Upstate Medical UniversityClass of 1996

Certifications & Licensure

GA State Medical License 2003 - 2025
MD State Medical License 2000 - 2004
American Board of Internal Medicine Medical Oncology

Clinical Trials

Valproic Acid in Treating Patients With Kaposi's Sarcoma Start of enrollment: 2005 Feb 01
Completed
Not Applicable
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma Start of enrollment: 2011 Jun 21
Completed
Phase 1
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
Completed
Phase 3
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma Start of enrollment: 2013 Mar 07
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

65 citations
Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC.
Elise A. Olsen, Sean Whittaker, Rein Willemze, Lauren C. Pinter-Brown, Francine M. Foss
Blood. 2021-11-10
329 citations
International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease
David C. Fajgenbaum, Thomas S. Uldrick, Adam Bagg, Dale Frank, David Wu
Blood. 2017-03-23
129 citations
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC...
Kieron Dunleavy, Michelle A. Fanale, Jeremy S. Abramson, Ariela Noy, Paolo Caimi
The Lancet. Haematology. 2018-12-01

Abstracts/Posters

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
Mary Jo Lechowicz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evaluation of Maintenance Therapy in Cutaneous T-Cell Lymphoma Patients Receiving Total Skin Electron Beam Radiation Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Professional Memberships

American Society of Clinical Oncology - ASCO
Member